City

Guangzhou (1)

Condition

BRAF V600E Metastatic NSCLC (1)

BRAF V600E Unresectable or Metastatic Melanoma (1)

Melanoma (1)

Overall Status

Completed (1)

Sign in for free

Phase

phase 1 (1)

Sponsor

Pierre Fabre Medicament (1)

Collaborator

Intervention

encorafenib (1)

Study Documents

Intervention Type

drug (1)

Funder Type

Industry (1)

Study Type

Interventional (1)

braf v600e metastatic nsclc

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC, Melanoma Trial in Guangzhou (Encorafenib)

Completed

BRAF V600E Unresectable or Metastatic Melanoma
+2 more

Encorafenib

Guangzhou, Guangdong, China

Sun Yat-sen University Cancer Center

Jun 9, 2022